Instrument Inactif

Autres langues Pulmatrix Inc Nasdaq

Actions

US74584P1030

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	30/05
MannKind Agrees to Cross License Deal With Pulmatrix	29/05
Pulmatrix Files Up to $95 Million Mixed Shelf	17/05
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine	16/05
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine	15/05
Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K	15/05
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update	13/05
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M	10/05
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	13/03
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives	09/01
Pulmatrix Explores Strategic Alternatives	08/01
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives	08/01
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	08/01
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update	10/11
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M	09/11
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine	20/09/23
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	24/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pulmatrix Inc Nasdaq

Actions

US74584P1030

Autres langues

Filtres